Radioligand Therapy: Opening a new chapter in Chinese medical innovation

Novartis recently announced its investment in a new radiopharmaceutical production facility in Haiyan County, Zhejiang Province, China. The total investment is expected to exceed 600 million yuan. The move is aimed at accelerating the introduction of innovative radioligand therapy to meet the clinical needs of cancer patients in the country. Production is expected to begin by the end of 2026, subject to regulatory approval. As a global leader in the pharmaceutical industry, Novartis' investment in radioligand therapy not only expands its influence in the global pharmaceutical market, but also marks a new phase in the development of China's healthcare industry.

Technological Innovation in Radioligand Therapy

Radioligand therapy is a treatment method that uses radiolabelled ligands to target tumour cells and kill them directly with radiation energy. Its advantage over traditional chemotherapy and radiotherapy lies in its ability to precisely localise tumour cells, minimising damage to healthy cells and providing a safer and more effective treatment. The application of this technology marks a new era in cancer treatment.

Pamedic Holdings is a company specialising in the research and production of medical isotopes. It was established in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone in Futian District, Shenzhen. Initiated by Hong Kong's C Cheng Holdings Limited, MWA.T Industrial Consultants and the UK's PMHL, the company aims to promote innovation in nuclear medicine. Its core technical team consists of top isotope talents from China and the UK. Pamedic is dedicated to the research and production of isotopes and ligands, which are special pharmaceutical preparations composed of radioactive isotopes and molecular reagents specific to certain organs and tissues. Nuclear medicine has a wide range of applications in medical imaging diagnosis and clinical treatment. In diagnosis, medical isotopes provide information at the molecular level, allowing early detection of lesions that have not yet undergone morphological changes. In terms of treatment, nuclear medicine technology allows small lesions to be targeted with radioactive isotopes, marking a new era in cancer treatment.

In addition, the radiopharmaceutical industry has become a strategically supported emerging industry in China, with development plans and policy documents from relevant national departments. Against this backdrop, more and more industry leaders are showing greater interest in investing and expanding, which will further promote the development of China's nuclear medicine industry and contribute to the long-term development of the pharmaceutical and healthcare industries.

Development potential of China's pharmaceutical market

The rapid development of China's pharmaceutical market provides a fertile ground for the introduction of radioligand therapy.

The radiopharmaceutical industry has become a key strategically supported emerging industry in China, and is one of the fundamental industries promoting the high-quality development of the healthcare sector. In June 2021, the National Defence Science and Technology Industry Bureau, the Ministry of Science and Technology, the Ministry of Public Security, the Ministry of Ecology and Environment, the Ministry of Transportation, the National Health Commission, the National Medical Insurance Administration and the National Medical Products Administration issued the "Mid- to Long-term Development Plan for Medical Isotopes (2021-2035)", which sets the overall framework for the further development of the radiopharmaceutical industry.

In April 2023, the National Drug Administration issued the "Opinions on Reforming and Improving the Evaluation and Approval Management System for Radiopharmaceuticals", which encourages innovation in radiopharmaceuticals based on clinical value and promotes the import registration of original research radiopharmaceuticals already on the overseas market. It also proposed to prioritise the evaluation and approval of marketing authorisations for radiopharmaceuticals that are urgently needed in clinical practice.

The Chinese government's support for the pharmaceutical industry and growing medical demand are creating favourable conditions for the promotion and use of this emerging treatment. The investments made by industry leaders in China not only accelerate the localisation of radioligand therapy, but also contribute to the overall technological advancement of the Chinese healthcare industry.

In conclusion, the introduction of radioligand therapy is not only a reflection of advances in medical technology, but also an important opportunity for the development of the Chinese pharmaceutical market. With many nuclear medicine research and development companies coming together, it heralds a new phase of development for China's healthcare industry, providing more treatment options for patients and new growth points for investors.